Inovio Pharmaceuticals Inc INO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 11:16 AM EDT
11.88quote price arrow up+0.43 (+3.76%)
Volume
143,599
52 week range
3.89 - 14.75
Loading...
  • Open11.47
  • Day High12.39
  • Day Low11.41
  • Prev Close11.45
  • 52 Week High14.75
  • 52 Week High Date04/01/24
  • 52 Week Low3.89
  • 52 Week Low Date11/10/23

Key Stats

  • Market Cap300.912M
  • Shares Out25.33M
  • 10 Day Average Volume0.32M
  • Dividend-
  • Dividend Yield-
  • Beta1.16
  • YTD % Change98.45

KEY STATS

  • Open11.47
  • Day High12.39
  • Day Low11.41
  • Prev Close11.45
  • 52 Week High14.75
  • 52 Week High Date04/01/24
  • 52 Week Low3.89
  • 52 Week Low Date11/10/23
  • Market Cap300.912M
  • Shares Out25.33M
  • 10 Day Average Volume0.32M
  • Dividend-
  • Dividend Yield-
  • Beta1.16
  • YTD % Change98.45

RATIOS/PROFITABILITY

  • EPS (TTM)-6.15
  • P/E (TTM)-1.93
  • Fwd P/E (NTM)-3.08
  • EBITDA (TTM)-128.66M
  • ROE (TTM)-79.55%
  • Revenue (TTM)832,009.971
  • Gross Margin (TTM)-
  • Net Margin (TTM)-16,239.87%
  • Debt To Equity (MRQ)14.29%

EVENTS

  • Earnings Date05/13/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Inovio Pharmaceuticals Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or...
Simon Benito
Independent Chairman of the Board
Jacqueline Shea Ph.D.
President, Chief Executive Officer, Director
Peter Kies
Chief Financial Officer
Address
6769 Mesa Ridge Rd.
San Diego, CA
92121
United States

Top Peers

SYMBOLLASTCHG%CHG
CRDF
Cardiff Oncology Inc
4.19-0.17-3.90%
CADL
Candel Therapeutics Inc
7.33+0.28+3.97%
ABOS
Acumen Pharmaceuticals Inc
3.15-0.07-2.17%
TRVI
Trevi Therapeutics Inc
2.88-0.05-1.71%
ATOS
Atossa Therapeutics Inc
1.50-0.01-0.66%